Citation: Rr. Berardi et Ls. Welage, PROTON-PUMP INHIBITORS IN ACID-RELATED DISEASES, American journal of health-system pharmacy, 55(21), 1998, pp. 2289-2298
Authors:
RHIE JK
HAYASHI Y
WELAGE LS
FRENS J
WALD RJ
BARNETT JL
AMIDON GE
PUTCHA L
AMIDON GL
Citation: Jk. Rhie et al., DRUG MARKER ABSORPTION IN RELATION TO PELLET SIZE, GASTRIC-MOTILITY AND VISCOUS MEALS IN HUMANS, Pharmaceutical research, 15(2), 1998, pp. 233-238
Authors:
NEUDECK BL
TADDONIO TE
GARNER WL
WELAGE LS
Citation: Bl. Neudeck et al., DETERMINATION OF FLUOXETINE AND NORFLUOXETINE CONCENTRATIONS IN CADAVERIC ALLOGRAFT SKIN, Pharmacotherapy, 18(4), 1998, pp. 851-855
Citation: Be. Bleske et al., PHARMACOKINETICS OF TORSEMIDE IN PATIENTS WITH DECOMPENSATED AND COMPENSATED CONGESTIVE-HEART-FAILURE, Journal of clinical pharmacology, 38(8), 1998, pp. 708-714
Authors:
TAKAMATSU N
WELAGE LS
IDKAIDEK NM
LIU DY
LEE PID
HAYASHI Y
RHIE JK
LENNERNAS H
BARNETT JL
SHAH VP
LESKO L
AMIDON GL
Citation: N. Takamatsu et al., HUMAN INTESTINAL PERMEABILITY OF PIROXICAM, PROPRANOLOL, PHENYLALANINE, AND PEG-400 DETERMINED BY JEJUNAL PERFUSION, Pharmaceutical research, 14(9), 1997, pp. 1127-1132
Authors:
TIMM EG
WELAGE LS
WALAWANDER CA
SAYERS JFB
KARPIUK EL
DAVIS TD
GRASELA TH
Citation: Eg. Timm et al., ADVERSE DRUG REACTION REPORTING IN A MULTICENTER SURVEILLANCE STUDY, The Annals of pharmacotherapy, 29(3), 1995, pp. 240-245
Authors:
WELAGE LS
CARVER PL
REVANKAR S
PIERSON C
KAUFFMAN CA
Citation: Ls. Welage et al., ALTERATIONS IN GASTRIC-ACIDITY IN PATIENTS INFECTED WITH HUMAN-IMMUNODEFICIENCY-VIRUS, Clinical infectious diseases, 21(6), 1995, pp. 1431-1438
Authors:
WELAGE LS
MASON NA
HOFFMAN EJ
ODEH RM
DOMBROUSKI J
PATEL JA
SWARTZ RD
Citation: Ls. Welage et al., INFLUENCE OF CELLULOSE TRIACETATE HEMODIALYZERS ON VANCOMYCIN PHARMACOKINETICS, Journal of the American Society of Nephrology, 6(4), 1995, pp. 1284-1290
Authors:
BLESKE BE
WELAGE LS
WARREN EW
BROWN MB
SHEA MJ
Citation: Be. Bleske et al., VARIATIONS IN PROTHROMBIN TIME AND INTERNATIONAL NORMALIZED RATIO OVER 24 HOURS IN WARFARIN-TREATED PATIENTS, Pharmacotherapy, 15(6), 1995, pp. 709-712
Authors:
WELAGE LS
DUNNKUCHARSKI VA
BERARDI RR
SHEA MJ
DECHERT RE
BLESKE BE
Citation: Ls. Welage et al., COMPARATIVE-EVALUATION OF THE HEMODYNAMIC-EFFECTS OF ORAL CIMETIDINE,RANITIDINE, AND FAMOTIDINE AS DETERMINED BY ECHOCARDIOGRAPHY, Pharmacotherapy, 15(2), 1995, pp. 158-163
Authors:
CONBOY K
WELAGE LS
WALAWANDER CA
DUFFY LC
WELLIVER RC
ZIELEZNY MA
DIPIRO JT
RAEBEL MA
GRASELA TH
Citation: K. Conboy et al., SEPSIS SYNDROME AND ASSOCIATED SEQUELAE IN PATIENTS AT HIGH-RISK FOR GRAM-NEGATIVE SEPSIS, Pharmacotherapy, 15(1), 1995, pp. 66-77
Authors:
BLESKE BE
WELAGE LS
ROSE S
AMIDON GL
SHEA MJ
Citation: Be. Bleske et al., THE EFFECT OF DOSAGE RELEASE FORMULATIONS ON THE PHARMACOKINETICS OF PROPRANOLOL STEREOISOMERS IN HUMANS, Journal of clinical pharmacology, 35(4), 1995, pp. 374-378
Authors:
WELAGE LS
WALAWANDER CA
TIMM EG
GRASELA TH
Citation: Ls. Welage et al., RISK-FACTORS FOR ACUTE RENAL-INSUFFICIENCY IN PATIENTS WITH SUSPECTEDOR DOCUMENTED BACTERIAL PNEUMONIA, The Annals of pharmacotherapy, 28(4), 1994, pp. 515-522
Authors:
PALADINO JA
RAINSTEIN MA
SERRIANNE DJ
PRZYLUCKI JE
WELAGE LS
COLLURA ML
SCHENTAG JJ
Citation: Ja. Paladino et al., AMPICILLIN-SULBACTAM VERSUS CEFOXITIN FOR PROPHYLAXIS IN HIGH-RISK PATIENTS UNDERGOING ABDOMINAL-SURGERY, Pharmacotherapy, 14(6), 1994, pp. 734-739
Authors:
BLESKE BE
WELAGE LS
TOUCHETTE MA
EDWARDS DJ
RODMAN DP
SHEA MJ
Citation: Be. Bleske et al., EVALUATION OF DOSAGE-RELEASE FORMULATIONS ON INHIBITION OF DRUG CLEARANCE - EFFECT OF SUSTAINED-RELEASE AND IMMEDIATE-RELEASE VERAPAMIL ON PROPRANOLOL PHARMACOKINETIC PARAMETERS, Therapeutic drug monitoring, 16(2), 1994, pp. 216-220